Business Wire

  1. Sail Biomedicines Announces Strategic Collaboration To Develop New Class Of Medicines For In Vivo CAR-T 7/29/2026

    Sail Biomedicines, a Flagship Pioneering company creating a new class of RNA medicines, today announced a strategic collaboration with Johnson & Johnson to advance innovative In Vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies that have the potential to improve patient outcomes for immune-mediated diseases.

  2. HAYA Therapeutics Receives FDA Fast Track Designation For HTX-001 7/28/2026

    HAYA Therapeutics SA, a clinical-stage biotechnology company pioneering precision RNA-guided therapeutics that target the regulatory genome to reprogram disease-driving cell states in common, chronic and age-related diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).

  3. Enveric Biosciences Welcomes Final FDA Guidance For Psychedelic Drug Development 7/28/2026

    Enveric Biosciences (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.

  4. MindWalk Showcases ReefIQ For AI Drug Discovery At AMD Advancing AI 7/23/2026

    MindWalk Holdings Corp. (“MindWalk”), a Bio-Native AI company, today unveiled the first public demonstration of ReefIQ, its biological context layer for AI drug discovery, running on AMD Instinct at AMD’s Advancing AI 2026 in San Francisco.

  5. Thyora Therapeutics Launches To Build A Next-Generation Platform For Covalent Drug Discovery 7/23/2026

    Thyora Therapeutics today emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs.

  6. GCCL And GemPharmatech Sign MOU To Advance Global Drug Discovery And Development Services 7/22/2026

    GCCL, a South Korea-based leading provider of clinical trial sample analysis, and GemPharmatech, a global provider of in vivo efficacy testing and genetically engineered animal models, announced the signing of a Memorandum of Understanding (MOU) to promote mutual collaboration in delivering integrated drug discovery and development services to pharmaceutical and biotechnology companies worldwide.

  7. TriLink BioTechnologies Further Strengthens Global IP Position With Newly Issued Patent In China For CleanCap Capping Technology 7/20/2026

    TriLink BioTechnologies, LLC (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules.

  8. Crown Bioscience Joins C-Path's NAMs Developer Coalition To Advance Human-Relevant Models In Drug Development 7/16/2026

    Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined Critical Path Institute's (C-Path) New Approach Methodologies Developer Coalition (NAMs-DC), a collaborative initiative dedicated to advancing the validation, qualification and regulatory adoption of innovative human-relevant research methods.

  9. Anova And Nouveau Biosciences Announce Partnership To Deliver Clinical Trials Of Kromastat For The Treatment Of Relapsed Or Refractory Cutaneous And Peripheral T-Cell Lymphoma 7/15/2026

    Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, today announced its partnership with Nouveau Biosciences, Inc. to conduct cancer focused clinical trials for their lead asset Kromastat. Nouveau Biosciences is a biotechnology company pioneering novel targeted nanomedicines to improve cancer therapy.

  10. Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation And European Medicines Agency Orphan Medicinal Product Designation (OMPD) For NB4168 For The Treatment Of Ataxia Telangiectasia (A-T) 7/13/2026

    Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T).